Alexandria Co. For Pharmaceuticals & Chemical Industries (EGX: AXPH)
Egypt
· Delayed Price · Currency is EGP 229.03
0.00 (0.00%)
At close: Sep 12, 2024
AXPH Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2014 |
| Operating Revenue | 1,801 | 1,484 | 1,100 | 1,104 | 1,015 | 829.04 | Upgrade
|
| Other Revenue | - | - | 0 | - | 9.87 | - | Upgrade
|
| Revenue | 1,801 | 1,484 | 1,100 | 1,104 | 1,025 | 829.04 | Upgrade
|
| Revenue Growth (YoY) | 56.02% | 34.94% | -0.38% | 7.75% | 23.61% | 17.81% | Upgrade
|
| Cost of Revenue | 1,418 | 1,223 | 876.78 | 841.45 | 703.59 | 609.23 | Upgrade
|
| Gross Profit | 382.88 | 260.89 | 223.24 | 262.8 | 321.23 | 219.81 | Upgrade
|
| Selling, General & Admin | 84.91 | 83.52 | 75.65 | 93.71 | 86.44 | 67.09 | Upgrade
|
| Other Operating Expenses | 43.99 | 22.44 | 13.05 | 14.98 | 13.09 | 6.93 | Upgrade
|
| Operating Expenses | 128.9 | 105.96 | 88.7 | 108.69 | 99.53 | 74.02 | Upgrade
|
| Operating Income | 253.99 | 154.92 | 134.54 | 154.11 | 221.7 | 145.8 | Upgrade
|
| Interest & Investment Income | 10.12 | 5.52 | 5.55 | 2.82 | 2.82 | 13.4 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.55 | 11.57 | 4.4 | -0.24 | 0.1 | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | 0 | 0 | -12.27 | Upgrade
|
| EBT Excluding Unusual Items | 268.65 | 172.02 | 144.49 | 156.69 | 224.61 | 146.93 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.75 | 1.03 | - | 0.4 | 0.49 | - | Upgrade
|
| Other Unusual Items | 4.9 | -8.1 | -0.99 | -5.5 | -4.29 | - | Upgrade
|
| Pretax Income | 274.31 | 164.95 | 143.5 | 151.59 | 220.82 | 146.93 | Upgrade
|
| Income Tax Expense | 64.21 | 38.52 | 26.08 | 34.59 | 50.77 | 34.08 | Upgrade
|
| Net Income | 210.1 | 126.43 | 117.42 | 117 | 170.05 | 112.85 | Upgrade
|
| Net Income to Common | 210.1 | 126.43 | 117.42 | 117 | 170.05 | 112.85 | Upgrade
|
| Net Income Growth | 70.33% | 7.67% | 0.36% | -31.20% | 50.68% | -4.54% | Upgrade
|
| Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 6 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 6 | 6 | Upgrade
|
| Shares Change (YoY) | - | - | - | -15.35% | -5.58% | 3.30% | Upgrade
|
| EPS (Basic) | 42.02 | 25.29 | 23.48 | 23.40 | 28.79 | 18.04 | Upgrade
|
| EPS (Diluted) | 42.02 | 25.29 | 23.48 | 23.40 | 28.79 | 18.04 | Upgrade
|
| EPS Growth | - | 7.67% | 0.36% | -18.72% | 59.59% | -7.58% | Upgrade
|
| Free Cash Flow | 85.64 | 7.09 | 160.9 | -20.57 | 68.57 | 124.72 | Upgrade
|
| Free Cash Flow Per Share | 17.13 | 1.42 | 32.18 | -4.11 | 11.61 | 19.94 | Upgrade
|
| Dividend Per Share | 13.000 | 13.000 | - | 10.000 | 15.500 | 11.200 | Upgrade
|
| Dividend Growth | - | - | - | -35.48% | 38.39% | 24.44% | Upgrade
|
| Gross Margin | 21.26% | 17.58% | 20.29% | 23.80% | 31.34% | 26.51% | Upgrade
|
| Operating Margin | 14.10% | 10.44% | 12.23% | 13.96% | 21.63% | 17.59% | Upgrade
|
| Profit Margin | 11.67% | 8.52% | 10.67% | 10.60% | 16.59% | 13.61% | Upgrade
|
| Free Cash Flow Margin | 4.75% | 0.48% | 14.63% | -1.86% | 6.69% | 15.04% | Upgrade
|
| EBITDA | 291.9 | 182.92 | 157.73 | 177.74 | 244.15 | 165.47 | Upgrade
|
| EBITDA Margin | 16.21% | 12.32% | 14.34% | 16.10% | 23.82% | 19.96% | Upgrade
|
| D&A For EBITDA | 37.91 | 28 | 23.18 | 23.63 | 22.45 | 19.67 | Upgrade
|
| EBIT | 253.99 | 154.92 | 134.54 | 154.11 | 221.7 | 145.8 | Upgrade
|
| EBIT Margin | 14.10% | 10.44% | 12.23% | 13.96% | 21.63% | 17.59% | Upgrade
|
| Effective Tax Rate | 23.41% | 23.35% | 18.17% | 22.82% | 22.99% | 23.19% | Upgrade
|
| Revenue as Reported | 1,807 | 1,486 | 1,101 | 1,111 | 1,025 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.